Gene targeting by ribozyme against TNF-α mRNA inhibits autoimmune arthritis

Gene Therapy

Volumn 12, Issue 20, 2005, Pages 1486-1493

  Kumar, R ^a,b   Dammai, V ^b   Yadava, P K ^b   Kleinau, S ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

Autoimmunity; Cytokines; Inflammation; Rodent

Indexed keywords

COLLAGEN TYPE 2; HAMMERHEAD RIBOZYME; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; BONE DESTRUCTION; CARTILAGE DEGENERATION; CATALYSIS; CHRONIC INFLAMMATION; CONTROLLED STUDY; FEMALE; GENE DELIVERY SYSTEM; GENE TARGETING; IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ARTHRITIS, RHEUMATOID; FEMALE; GENE TARGETING; GENE THERAPY; IMMUNOGLOBULIN G; INJECTIONS, INTRA-ARTERIAL; MALE; MICE; MICE, INBRED DBA; RNA, CATALYTIC; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

RODENTIA;

EID: 27144434561     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302583     Document Type: Article

References (47)

1. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33: 305-315.
2. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397-440.
3. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995; 38: 151-160.
4. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163-196.
5. Saklatvala J. Tumour necrosis factor alpha stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature 1986; 322: 547-549.
6. Bertolini DR et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986; 319: 516-518.
7. Philip R, Epstein LB. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1. Nature 1986; 323: 86-89.
8. Engelberts I, von Asmuth EJ, van der Linden CJ, Buurman WA. The interrelation between TNF, IL-6, and PAF secretion induced by LPS in an in vivo and in vitro murine model. Lymphokine Cytokine Res 1991; 10: 127-131.
9. Thorens B, Mermod JJ, Vassalli P. Phagocytosis and inflammatory stimuli induce GM-CSF mRNA in macrophages through posttranscriptional regulation. Cell 1987; 48: 671-679.
10. Nandakumar KS et al. Induction of arthritis by single monoclonal IgG anti-collagen type II antibodies and enhancement of arthritis in mice lacking inhibitory FcgammaRIIB. Eur J Immunol 2003; 33: 2269-2277.
11. Keffer J et al. Transgenic mice expressing human tumor necrosis factor: a predictive model of arthritis. EMBO J 1991; 10: 4025-4031.
12. Thorbecke GJ et al. Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992; 89: 7375-7379.
13. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89: 9784-9788.
14. Piguet PF et al. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumor necrosis factor (TNF) antibody or recombinant soluble TNF receptor. Immunology 1992; 77: 510-514.
15. Elliott MJ et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 1993; 36: 1681-1690.
16. Elliott MJ et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-1110.
17. Elliott MJ et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125-1127.
18. Moreland LW et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997; 337: 141-147.
19. Rankin EC et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34: 334-342.
20. Zaug AJ, Cech TR. The intervening sequence RNA of tetrahymena is an enzyme. Science 1986; 231: 470-475.
21. Uhlenbeck OC. A small catalytic oligoribonucleotide. Nature 1987; 328: 596-600.
22. Haseloff J, Gerlach WL. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 1988; 334: 585-591.
23. Weinberg M, Passman M, Kew M, Arbuthnot P. Hammerhead ribozyme-mediated inhibition of hepatitis B virus X gene expression in cultured cells. J Hepatol 2000; 33: 142-151.
24. Jarvis TC et al. Ribozymes as tools for therapeutic target validation in arthritis. J Immunol 2000; 165: 493-498.
25. Kim YK et al. Repression of hepatitis B virus X gene expression by hammerhead ribozymes. Biochem Biophys Res Commun 1999; 257: 759-765.
26. Flory CM et al. Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint. Proc Natl Acad Sci USA 1996; 93: 754-758.
27. Kitajima I et al. Ribozyme-based gene cleavage approach to chronic arthritis associated with human T cell leukemia virus type I: Induction of apoptosis in synoviocytes by ablation of HTLV-1 tax protein. Arthritis Rheum 1997; 40: 2118-2127.
28. Takahashi M et al. Chemically modified ribozyme targeting TNF-alpha mRNA regulates TNF-alpha and IL-6 synthesis in synovial fibroblasts of patients with rheumatoid arthritis. J Clin Immunol 2002; 22: 228-236.
29. Rutkauskaite E et al. Ribozymes that inhibit the production of matrix metalloproteinase 1 reduce the invasiveness of rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2004; 50: 1448-1456.
30. Schedel J et al. Targeting cathepsin L (CL) by specific ribozymes decreases CL protein synthesis and cartilage destruction in rheumatoid arthritis. Gene Therapy 2004; 11: 1040-1047.
31. Zuker M. On finding all suboptimal foldings of an RNA molecule. Science 1989; 244: 48-52.
32. Stuart JM, Dixon FJ. Serum transfer of collagen-induced arthritis in mice. J Exp Med 1983; 158: 378-392.
33. Wooley PH et al. Type II collagen-induced arthritis in mice. II. Passive transfer and suppression by intravenous injection of anti-type II collagen antibody or free native type II collagen. Arthritis Rheum 1984; 27: 1010-1017.
34. Herweijer H, Wolff JA. Progress and prospects: Naked DNA gene transfer and therapy. Gene Therapy 2003; 10: 453-458.
35. Yovandich J, O'Malley Jr B, Sikes M, Ledley FD. Gene transfer to synovial cells by intra-articular administration of plasmid DNA. Hum Gene Ther 1995; 6: 603-610.
36. Sioud M, Natvig JB, Forre O. Preformed ribozyme destroys tumour necrosis factor mRNA in human cells. J Mol Biol 1992; 223: 831-835.
37. MacKay SL et al. Characterization in vitro and in vivo of hammerhead ribozymes directed against murine tumor necrosis factor alpha. Biochem Biophys Res Commun 1999; 260: 390-397.
38. Kisich KO, Malone RW, Feldstein PA, Erickson KL. Specific inhibition of macrophage TNF-alpha expression by in vivo ribozyme treatment. J Immunol 1999; 163: 2008-2016.
39. Sioud M. Ribozyme modulation of lipopolysaccharide-induced tumor necrosis factor-alpha production by peritoneal cells in vitro and in vivo. Eur J Immunol 1996; 26: 1026-1031.
40. Mussener A, Klareskog L, Lorentzen JC, Kleinau S. TNF-alpha dominates cytokine mRNA expression in lymphoid tissues of rats developing collagen- and oil-induced arthritis. Scand J Immunol 1995; 42: 128-134.
41. Barrera P et al. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis. Ann Rheum Dis 2001; 60: 660-669.
42. Morishita R et al. Molecular delivery system for antisense oligonucleotides: Enhanced effectiveness of antisense oligonucleotides by HVJ-liposome mediated transfer. J Cardiovasc Pharmacol Ther 1997; 2: 213-222.
43. Jackson JK et al. The encapsulation of ribozymes in biodegradable polymeric matrices. Int J Pharm 2002; 243: 43-55.
44. Giulietti A et al. An overview of real-time quantitative PCR: applications to quantify cytokine gene expression. Methods 2001; 25: 386-401.
45. Kleinau S, Martinsson P, Gustavsson S, Heyman B. Importance of CD23 for collagen-induced arthritis: Delayed onset and reduced severity in CD23-deficient mice. J Immunol 1999; 162: 4266-4270.
46. Stahl TD et al. Expression of FcgammaRIII is required for development of collagen-induced arthritis. Eur J Immunol 2002; 32: 2915-2922.
47. Kleinau S, Erlandsson H, Holmdahl R, Klareskog L. Adjuvant oils induce arthritis in the DA rat. I. Characterization of the disease and evidence for an immunological involvement. J Autoimm 1991; 4: 871-880.